Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Moderna and CytomX to partner in deal worth up to 1.2bn

Moderna and CytomX to partner in deal worth up to 1.2bn

CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • ASH 2022: bad blood but big advances ASH 2022: bad blood but big advances

    Multiple myeloma was a major focus, with data presentations on emerging and approved bispecific antibodies and CAR-T therapies showcasing promising approaches for heavily pre-treated patients. ... One particular session on bispecific antibodies attracted

  • Putting the ovation into innovation: trends from ESMO Putting the ovation into innovation: trends from ESMO

    toxicity, including innovative bispecific monoclonal antibodies and Bi-specific T-cell engagers.

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...